Study Using a Handheld Mass Spectrometry Device to Identify Metabolic Markers for Fast Diagnosis and Surgical Assessment of MPNST and Neurofibromas

What this Trial Is About

This research aims to learn if a handheld Mass Spectrometry device called the MasSpec Pen can accurately identify malignant peripheral nerve sheath tumors MPNST, neurofibroma, and normal nerve tissue during surgery. The study focuses on finding specific metabolic markers and validating the devices ability to help diagnose these conditions and assess surgical margins in real time. Participants with diagnosed MPNST or neurofibroma who are scheduled for surgical removal of these tumors as part of their usual care will be included. The study will analyze the metabolite and lipid profiles of the tumor and nerve tissues and test the handheld mass spectrometry device during surgery to evaluate its diagnostic accuracy and use in guiding surgical decisions. During the study, participants will undergo standard surgical procedures while researchers collect data using the device. Safety and any adverse events will be monitored throughout the study, which is expected to last about one year per participant. This observational study includes patients aged 1 year and older and will track how well the device performs in distinguishing tumor tissue during surgery.

DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins